C1orf158

Across TCGA pan-cancer cohorts, C1orf158 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated C1orf158 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher C1orf158 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C1orf158 expression acts as an unfavorable survival marker.

LUAD, SKCM, and LUSC are the cancer types where C1orf158 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.405	0.814	<.001	24	view →
SKCM	DFS	Median	II,III,IV	0.196	0.598	.002	16	view →
LUSC	OS	Median	All	0.081	0.818	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

C1orf158–LUAD (OS)

Open the LUAD breakdown →